- Global Pharma News & Resources

US Cancer Biosimilar Market Opportunity Insight: Upwards of US$ 10 Billion by 2026 -

DUBLIN--(BUSINESS WIRE)--The "US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to's offering.

Over the past few years, there has been a growing race to develop an enhanced version of the cancer therapeutics market at the global level. To acquire such growing parameters, the US cancer market started intensifying the importance of the cancer antibody market by making itself among the top markets to establish a complete set of research paradigms important for the respective market. The US cancer antibody market has increased the overall market growth rate and size of the oncology sector, as the respective market carries the ability to optimize the high-ending demands of the cancer patient population for having a stable and efficient therapy for different cancers. In addition, the extensive development rate of healthcare in the form of diagnosis and drug research and development is estimated to benefit the cancer-antibody drug market enormously when compared with other country's market.

Cancer antibodies have helped the researchers in leaning the entire cancer therapeutics market towards a great transition i.e. from delivering adverse side effects to receiving tons of healthcare benefits such as no adverse side effects or cancer recurrence. Also, the availability of prominent designing and research tools in the US has also helped scientific researchers to design potent cancer-antibody drugs in terms of functionality, quality, and cost. It can be witnessed for the US cancer antibody drug market that the potential impact of the market on the US cancer market is far ahead of the clinical implications observed for a large base of chemotherapeutics agents and many more.

The extensive and well-established base for the oncology sector and specifically cancer-antibody drug market has made the US industry share a big percentage to the global development in this respective market, despite of the fact that there are numerous emerging powers in the world. With excessive use of pharmacoeconomics, relaxed formularies as well as e-prescribing market, high number of payers and healthcare policy-makers are also assessing the market towards boosting the research and development platform of the market by adding monotherapy and bispecific therapy to it.

To an extensive level, it is witnessed that the rising volume of research activities and quality of data available in the country has driven the adoption rate of novel drug approvals and grants for research and development platform related to the market. In addition, the primary regulatory body in the country has also made greater use of fast-track methods for making the entire market boomed with breakthroughs and achievements. In the US, technology advancement is also considered a democratizing force for boosting the market paradigm for cancer-antibody drug market. Biotech and bio-pharmaceutical companies are also inducing patient-centric approaches for turning the simple cancer antibody market into a market full of off-to-strategies. In addition, the total spending of medicines in cancer-antibody drug market is expected to increase, thus leading to the adoption of novel wave for innovative and promising products. Some of the prominent factors that will be driving the US cancer antibody drug market are: pricing shifts and emergence and growth of biosimilars. In the respective research report, reported sales, growing trends and opportunities, the challenge for the future market has been compared, thus providing a realistic idea for the market.

Key Report Highlights:

  • US Cancer Antibodies Market Opportunity: > US$ 70 Billion by 2026
  • US Cancer Antibodies Market Growth: 100% Absolute Growth Till 2026
  • US Cancer Antibodies Market Size Opportunity by Therapeutic Class
  • Insight On Clinical Trials by Company, Indication, Patient Segment & Phase
  • Insight on FDA Approved 57 Cancer Antibodies Available in US Market
  • Price, Dosage, Patent & Sales Insight on Cancer Antibodies Available In Market
  • US Cancer Biosimilar Market Opportunity Insight: > US$ 10 Billion by 2026

Key Topics Covered:

1. US Cancer Antibodies Market Analysis

2. US Cancer Antibodies Market Segmentation by Therapeutic Class

3. US Breast Cancer Antibodies Market

4. US Blood Cancer Antibody Market

5. US Lung Cancer Antibody Market

6. US Colorectal Cancer Antibodies Market Overview

7. US Cancer Biosimilar Market

8. Global Peptide Cancer Therapeutics Clinical Trials Overview

9. US HER2 Inhibiting Antibodies - Availability, Dosage, Patent, Price & Sales Analysis

10. US VEGF/VEGFR Inhibiting Antibodies -Availability, Dosage, Patent, Price & Sales Analysis

11. US Antibody-Drug Conjugates - Availability, Dosage, Patent, Price & Sales Analysis

12. US CD20-Directed Antibody - Availability, Dosage, Patent, Price & Sales Analysis

13. US Bispecific Antibodies - Availability, Dosage, Patent, Price & Sales Analysis

14. CD52 Monoclonal Antibodies - Availability, Dosage, Patent, Price & Sales Analysis

15. CD38 Monoclonal Antibodies - Availability, Dosage, Patent, Price & Sales Analysis

16. Immune Checkpoint Inhibitor - Availability, Dosage, Patent, Price & Sales Analysis

17. EGFR Inhibitors - Availability, Dosage, Patent, Price & Sales Analysis

18. Combinational Antibodies - Availability, Dosage, Price & Sales Analysis

19. Others Cancer Targeting Antibodies of US - Availability, Dosage, Patent, Price & Sales Analysis

20. Competitive Landscape

  • Amgen
  • AryoGen Pharmed
  • AstraZeneca plc
  • Boehringer Ingelheim
  • Bristol Mayer Squibb
  • Daiichi Sankyo Company
  • Genentech
  • Immunomedics
  • Innovent Biologics
  • Jassen Pharmaceuticals
  • MacroGenics
  • mAbxience
  • Mylan
  • Outlook Therapeutics
  • Pfizer
  • Prestige Biopharma
  • Roche
  • Samsung Bio
  • Seagen

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 06-Apr-2021